Apogee Therapeutics' CEO Michael Henderson discusses today's 52 week maintenance data for the company's extended-dose IL-13 inhibitor it atopic dermatitis

He discusses the the data and how he compares it to Dupixent and other medicines on the market, how translatable the data might be to a phase 3 that will be up and running later this year, and what other data the company will have in the near future.